From: A 1,408 km bicycle tour with prostate cancer patients—results of a pilot study
T1 | T2 | T3 | T4 | p | |
---|---|---|---|---|---|
EORTC QLQC-30 | |||||
Quality of life | 73.81 ± 8.91 | 73.81 ± 10.12 | 82.14 ± 19.50 | 73.81 ± 13.11 | 0.447 |
Physical functioning | 98.09 ± 3.25 | 93.33 ± 5.44 | 98.10 ± 5.04 | 95.24 ± 9.97 | 0.139 |
Role functioning | 95.24 ± 12.60 | 95.24 ± 12.60 | 95.24 ± 12.60 | 88.10 ± 15.85 | 0.415 |
Cognitive functioning | 80.95 ± 24.40 | 76.19 ± 28.64 | 80.95 ± 17.82 | 90.48 ± 18.90 | 0.98 |
Social functioning | 85.71 ± 17.82 | 88.10 ± 15.85 | 92.86 ± 13.11 | 83.33 ± 16.67 | 0.321 |
Emotional functioning | 84.52 ± 18.28 | 75.00 ± 25.00 | 90.48 ± 13.11 | 79.76 ± 24.93 | 0.097 |
Fatigue | 15.87 ± 24.73 | 17.46 ± 23.00 | 9.52 ± 13.50 | 9.52 ± 13.50 | 0.246 |
Nausea/vomiting | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | k.A. |
Pain | 14.29 ± 20.25 | 4.76 ± 8.13 | 11.90 ± 20.89 | 19.05 ± 26.23 | 0.488 |
Dyspnea | 9.52 ± 25.20 | 14.29 ± 37.80 | 0 ± 0 | 9.52 ± 25.20 | 0.721 |
Insomnia | 23.81 ± 31.71 | 33.33 ± 27.22 | 23.81 ± 25.20 | 23.81 ± 31.71 | 0.825 |
Appetite loss | 0 ± 0 | 0 ± 0 | 4.76 ± 12.60 | 0 ± 0 | 0.415 |
Constipation | 4.76 ± 12.60 | 4.76 ± 12.60 | 4.76 ± 12.60 | 0 ± 0 | 0.415 |
Diarrhea | 4.76 ± 12.60 | 4.76 ± 12.60 | 4.76 ± 12.60 | 0 ± 0 | 0.761 |
Financial difficulties | 0 ± 0 | 0 ± 0 | 0 ± 0 | 4.76 ± 12.60 | 0.415 |
EORTC PR 25 | |||||
Sexual functioning | 59.52 ± 15.95 | 61.90 ± 22.55 | 54.76 ± 22.78 | 61.90 ± 32.62 | 0.73 |
Urinary symptoms | 22.88 ± 25.32 | 25.33 ± 25.95 | 22.29 ± 23.29 | 27.38 ± 25.06 | 0.07 |
Bowel symptoms | 3.57 ± 4.45 | 2.38 ± 4.06 | 2.38 ± 4.06 | 4.76 ± 6.56 | 0.66 |
Treatment-related symptoms | 19.84 ± 13.90 | 11.91 ± 16.17 | 8.41 ± 12.03 | 13.33 ± 14.55 | 0.008** (t1–t3: 0.006**) |